| Michael Mcrae, | |
|
777 N Raymond St, Boise, ID 83704-9251 | |
| (208) 514-2500 | |
| (208) 375-2217 |
| Full Name | Michael Mcrae |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 777 N Raymond St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043745805 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MRO-1628 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Home Care | Meridian, ID | Home health agency |
| St Luke's Nampa Medical Center | Nampa, ID | Hospital |
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Lukes Clinic-treasure Valley Llc | 4981878402 | 968 |
News Archive
Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.
A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.
Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.
The high estrogen levels that typically afford younger women protection from cardiovascular disease appear to instead multiply their risk if they have type 1 diabetes, researchers say.
› Verified 9 days ago
| Entity Name | St Lukes Clinic-treasure Valley Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.
A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.
Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.
The high estrogen levels that typically afford younger women protection from cardiovascular disease appear to instead multiply their risk if they have type 1 diabetes, researchers say.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Mcrae, 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 514-2500 | Michael Mcrae, 777 N Raymond St, Boise, ID 83704-9251 Ph: (208) 514-2500 |
News Archive
Senesco Technologies, Inc. reported today the completion of cohort 3 of its Phase 1b/2a clinical trial for its drug, SNS01-T, for the treatment of multiple myeloma and lymphoma. The Company has also received approval from its Data Review Committee to proceed to cohort 4, which is expected to require six evaluable patients.
A team of Spanish scientists has developed an intelligent nanodevice that lays the foundations for the future development of new therapies against aging. The device consists of nanoparticles that can selectively release drugs in aged human cells.
Omeros Corporation today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program.
The high estrogen levels that typically afford younger women protection from cardiovascular disease appear to instead multiply their risk if they have type 1 diabetes, researchers say.
› Verified 9 days ago
Dr. Maureen A Newman, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-302-5480 | |
Jessica A Evert, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-7350 | |
Tracy Adams, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 | |
Sarah A Hershman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 Fax: 208-375-2217 | |
Summer E Szumski, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 777 N Raymond St, Boise, ID 83704 Phone: 208-514-2500 Fax: 208-375-2217 | |
Dr. Thornton E Bryan Iii, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 701 E Parkcenter Blvd, Boise, ID 83706 Phone: 208-381-6500 Fax: 208-381-6505 | |
Irvin E Sackman Jr., MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 130 E Boise Ave, Boise, ID 83706 Phone: 208-345-4066 Fax: 208-345-4196 |